Srdan Verstovsek Selected Research

Essential Thrombocythemia

11/2021	Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice.
1/2021	Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
10/2020	Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
1/2018	SOHO State-of-the-Art Update and Next Questions: MPN.
11/2017	Ruxolitinib for essential thrombocythemia?
10/2017	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
10/2017	A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
1/2017	Developmental Therapeutics in Myeloproliferative Neoplasms.
1/2017	JAK2 inhibitors for myeloproliferative neoplasms: what is next?
1/2017	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Srdan Verstovsek Research Topics

Disease

174	Primary Myelofibrosis (Myelosclerosis) 07/2022 - 05/2006
111	Neoplasms (Cancer) 10/2022 - 05/2003
62	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2021 - 03/2002
57	Polycythemia Vera 01/2022 - 06/2006
53	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 11/2002
51	Splenomegaly 10/2021 - 10/2004
40	Anemia 01/2022 - 05/2005
36	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2020 - 07/2002
33	Philadelphia Chromosome 07/2020 - 05/2002
31	Essential Thrombocythemia 11/2021 - 01/2003
31	Leukemia 01/2021 - 05/2002
23	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 12/2003
21	Cytopenia 01/2022 - 05/2006
21	Thrombocytopenia (Thrombopenia) 01/2022 - 05/2006
20	Systemic Mastocytosis 12/2021 - 10/2006
18	Fibrosis (Cirrhosis) 06/2022 - 10/2009
14	Blast Crisis (Blast Phase) 01/2021 - 01/2006
13	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 10/2003
13	Fatigue 01/2017 - 01/2003
11	Acute Promyelocytic Leukemia 01/2022 - 05/2003
10	Myeloproliferative Disorders (Myeloproliferative Disorder) 09/2013 - 09/2003
8	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2022 - 08/2005
8	Inflammation (Inflammations) 04/2021 - 07/2014
8	Leukocytosis (Pleocytosis) 01/2019 - 12/2003
8	Infections 09/2018 - 03/2003
8	Thrombocytosis (Thrombocythemia) 02/2017 - 09/2003
7	Disease Progression 06/2022 - 05/2002
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 04/2003
7	Pathologic Complete Response 07/2020 - 01/2003
7	Multiple Myeloma 01/2018 - 05/2003
6	Thrombosis (Thrombus) 02/2017 - 05/2008
6	Diarrhea 01/2017 - 09/2006
5	Hemorrhage 01/2022 - 12/2015
5	Polycythemia (Erythrocytosis) 01/2021 - 08/2007
5	Myeloid Leukemia (Leukemia, Myelocytic) 01/2021 - 05/2003
5	Sepsis (Septicemia) 07/2020 - 11/2004
5	Lymphoma (Lymphomas) 01/2019 - 04/2006
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 05/2002
5	Pain (Aches) 03/2017 - 08/2003
4	Hypertension (High Blood Pressure) 04/2020 - 07/2006
4	Exanthema (Rash) 01/2020 - 01/2008
4	Headache (Headaches) 01/2017 - 08/2003
4	Pruritus (Itching) 01/2017 - 02/2014

Drug/Important Bio-Agent (IBA)

116	ruxolitinibIBA 06/2022 - 01/2009
44	Janus Kinase InhibitorsIBA 07/2022 - 01/2009
42	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 05/2002
34	Janus KinasesIBA 01/2022 - 02/2008
24	Janus Kinase 2IBA 05/2021 - 11/2005
22	Tyrosine Kinase InhibitorsIBA 11/2021 - 09/2003
20	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 05/2002
19	Pharmaceutical PreparationsIBA 01/2022 - 08/2003
18	CytokinesIBA 06/2022 - 01/2009
18	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2022 - 06/2006
18	Phosphotransferases (Kinase)IBA 01/2022 - 03/2006
16	InterferonsIBA 01/2021 - 06/2003
15	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2002
14	Janus Kinase 1IBA 01/2019 - 01/2013
13	Interferon-alpha (Interferon Alfa)IBA 10/2016 - 01/2003
12	Hemoglobins (Hemoglobin)IBA 01/2022 - 05/2005
12	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 01/2022 - 01/2017
11	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2022 - 03/2003
11	fedratinibIBA 01/2022 - 01/2019
11	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2022 - 01/2015
10	Lenalidomide (CC 5013)FDA Link 01/2018 - 08/2006
9	Biological ProductsIBA 05/2022 - 08/2003
9	Reticulin (Reticular Fiber)IBA 01/2022 - 10/2009
9	Arsenic Trioxide (Trisenox)FDA Link 01/2017 - 05/2003
8	Decitabine FDA Link 01/2021 - 06/2005
8	Dasatinib (BMS 354825)FDA Link 11/2020 - 06/2008
7	Alemtuzumab (Campath)FDA Link 01/2022 - 05/2003
7	ArsenicIBA 04/2016 - 05/2003
7	Prednisone (Sone)FDA LinkGeneric 01/2016 - 09/2009
6	IronIBA 01/2022 - 07/2006
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2021 - 05/2002
6	Clofarabine (Clolar)FDA Link 01/2021 - 10/2003
6	Gemtuzumab (Mylotarg)FDA Link 01/2017 - 03/2003
6	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2017 - 05/2003
6	Rituximab (Mabthera)FDA Link 11/2015 - 04/2003
5	Cladribine FDA LinkGeneric 01/2021 - 08/2005
5	fludarabineIBA 01/2020 - 03/2003
5	nilotinib FDA Link 01/2020 - 07/2005
5	Monoclonal AntibodiesIBA 01/2019 - 09/2004
5	Thalidomide (Thalomid)FDA Link 01/2018 - 05/2006
5	pomalidomideIBA 10/2017 - 09/2009
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2003 - 03/2002
4	imetelstatIBA 07/2022 - 01/2017
4	navitoclaxIBA 06/2022 - 01/2022
4	Messenger RNA (mRNA)IBA 01/2022 - 05/2002
4	avapritinibIBA 12/2021 - 01/2018
4	Erythropoietin FDA Link 01/2021 - 06/2008
4	Transaminases (Aminotransferases)IBA 01/2020 - 01/2008
4	CollagenIBA 01/2019 - 05/2015

Therapy/Procedure

200	Therapeutics 10/2022 - 01/2003
24	Drug Therapy (Chemotherapy) 01/2022 - 03/2003
10	Stem Cell Transplantation 01/2021 - 03/2003
9	Drug Tapering 11/2021 - 06/2003
7	Induction Chemotherapy 01/2017 - 11/2004
6	Immunotherapy 01/2021 - 03/2007
4	Cell Transplantation 12/2020 - 01/2016
4	Salvage Therapy 01/2020 - 08/2005